EC approves Padcev + Keytruda as perioperative treatment option for cisplatin-ineligible patients with resectable muscle-invasive bladder cancer

FDA expands Anktiva approval for BCG-unresponsive non-muscle-invasive bladder cancer to cover both papillary and CIS disease

FDA expanded the approved indication for Anktiva (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin to include patients with BCG-unresponsive NMIBC with papillary-only tumors.

October 16, 2026

Vol.52 No.38

Clinical Roundup

Urine test may improve bladder cancer diagnosis and guide treatment decision, Stanford-led study finds

A simple urine test devised by researchers at Stanford Medicine and the VA Palo Alto Health Care System can diagnose people with bladder cancer more accurately than current standard methods. The test also allows physicians to not only assess the cancer’s response to treatment but to predict whether immunotherapy or chemotherapy is likely to be most effective for each patient.

October 09, 2026

Vol.52 No.37

In Brief

Andrew Hsieh named Larry and Virginia Gordon Endowed Chair in Prostate and Bladder Cancer Research at Fred Hutch

Andrew Hsieh, who serves as the associate director of Fred Hutch’s Human Biology Division, has been named the inaugural holder of the Larry and Virginia Gordon Endowed Chair in Prostate and Bladder Cancer Research.

September 11, 2026

Vol.52 No.33

Drugs & Targets

EC approves Trodelvy + Keytruda for PD-L1 positive first-line metastatic TNBC

The European Commission has granted marketing authorization for Trodelvy (sacituzumab govitecan-hziy) in combination with Keytruda (pembrolizumab) for the treatment of adult patients with unresectable, locally advanced or metastatic triple-negative breast cancer who have not received prior systemic therapy for metastatic disease and whose tumors express PD-L1 with a combined positive score. Trodelvy plus Keytruda is...

September 11, 2026

Vol.52 No.33

Clinical Roundup

Enfortumab vedotin + pembrolizumab improves survival and reduces recurrence risk in muscle-invasive bladder cancer, phase III trial finds

Researchers have found that a combination of enfortumab vedotin and pembrolizumab helps patients with muscle-invasive bladder cancer live longer while reducing the risk that their cancer will return after surgery, according to the results of an international phase III clinical trial.

July 31, 2026

Vol.52 No.30

Drugs & Targets

EMA approves phase III clinical study of Alpha1H bladder cancer therapy

Alpha1H has received regulatory approval from the European Medicines Agency for its phase III clinical study of the therapy in bladder cancer. The approval represents a milestone for the clinical development of Alpha1H and provides a clear regulatory path toward a potential future marketing application in Europe.

July 24, 2026

Vol.52 No.29

EC approves Padcev + Keytruda as perioperative treatment option for cisplatin-ineligible patients with resectable muscle-invasive bladder cancer

YOU MAY BE INTERESTED IN

FDA expands Anktiva approval for BCG-unresponsive non-muscle-invasive bladder cancer to cover both papillary and CIS disease

Urine test may improve bladder cancer diagnosis and guide treatment decision, Stanford-led study finds

Andrew Hsieh named Larry and Virginia Gordon Endowed Chair in Prostate and Bladder Cancer Research at Fred Hutch

EC approves Trodelvy + Keytruda for PD-L1 positive first-line metastatic TNBC

Enfortumab vedotin + pembrolizumab improves survival and reduces recurrence risk in muscle-invasive bladder cancer, phase III trial finds

EMA approves phase III clinical study of Alpha1H bladder cancer therapy

Renew today!

Subscriber content

Never miss an issue!

Login